JPS5942683B2 - 必須金属イオン複合体 - Google Patents
必須金属イオン複合体Info
- Publication number
- JPS5942683B2 JPS5942683B2 JP52036878A JP3687877A JPS5942683B2 JP S5942683 B2 JPS5942683 B2 JP S5942683B2 JP 52036878 A JP52036878 A JP 52036878A JP 3687877 A JP3687877 A JP 3687877A JP S5942683 B2 JPS5942683 B2 JP S5942683B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- formula
- iron
- metal
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229910021645 metal ion Inorganic materials 0.000 title claims description 15
- 229910052751 metal Inorganic materials 0.000 claims description 48
- 239000002184 metal Substances 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 47
- 239000002253 acid Substances 0.000 claims description 36
- 229920002230 Pectic acid Polymers 0.000 claims description 21
- 239000010318 polygalacturonic acid Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 11
- 229910052749 magnesium Inorganic materials 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 9
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229910052750 molybdenum Inorganic materials 0.000 claims description 9
- 239000011733 molybdenum Substances 0.000 claims description 9
- 208000007502 anemia Diseases 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 239000000376 reactant Substances 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical group [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims 4
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical group [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 4
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical group [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical group [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 4
- BFGKITSFLPAWGI-UHFFFAOYSA-N chromium(3+) Chemical group [Cr+3] BFGKITSFLPAWGI-UHFFFAOYSA-N 0.000 claims 4
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical group [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims 4
- PSDQQCXQSWHCRN-UHFFFAOYSA-N vanadium(4+) Chemical compound [V+4] PSDQQCXQSWHCRN-UHFFFAOYSA-N 0.000 claims 4
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical group [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical group [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 68
- 239000000243 solution Substances 0.000 description 36
- 239000007864 aqueous solution Substances 0.000 description 33
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 31
- 229910052742 iron Inorganic materials 0.000 description 31
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 26
- 235000013350 formula milk Nutrition 0.000 description 23
- 239000010949 copper Substances 0.000 description 20
- 229910052802 copper Inorganic materials 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 17
- 229910017052 cobalt Inorganic materials 0.000 description 17
- 239000010941 cobalt Substances 0.000 description 17
- 239000012153 distilled water Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 14
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000011651 chromium Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052804 chromium Inorganic materials 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 239000011701 zinc Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229910000365 copper sulfate Inorganic materials 0.000 description 8
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 8
- 229910000358 iron sulfate Inorganic materials 0.000 description 8
- 239000011572 manganese Substances 0.000 description 8
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000004021 humic acid Substances 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 229910000361 cobalt sulfate Inorganic materials 0.000 description 6
- 229940044175 cobalt sulfate Drugs 0.000 description 6
- KTVIXTQDYHMGHF-UHFFFAOYSA-L cobalt(2+) sulfate Chemical compound [Co+2].[O-]S([O-])(=O)=O KTVIXTQDYHMGHF-UHFFFAOYSA-L 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229910052748 manganese Inorganic materials 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000008279 sol Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000008240 homogeneous mixture Substances 0.000 description 5
- 150000002739 metals Chemical class 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 229910052759 nickel Inorganic materials 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052720 vanadium Inorganic materials 0.000 description 4
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002211 L-ascorbic acid Substances 0.000 description 3
- 235000000069 L-ascorbic acid Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 description 3
- 229960001763 zinc sulfate Drugs 0.000 description 3
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920004933 Terylene® Polymers 0.000 description 2
- CMSMVCJLKKVEPN-SQSKPOSDSA-K [Mg+2].[K+].O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O Chemical compound [Mg+2].[K+].O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O.O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O CMSMVCJLKKVEPN-SQSKPOSDSA-K 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004688 heptahydrates Chemical class 0.000 description 2
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 2
- 239000012493 hydrazine sulfate Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940071125 manganese acetate Drugs 0.000 description 2
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical compound [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- -1 salt hydroxide Chemical class 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000005287 vanadyl group Chemical group 0.000 description 2
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000002492 Rungia klossii Nutrition 0.000 description 1
- 244000117054 Rungia klossii Species 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- OBLMUVZPDITTKB-UHFFFAOYSA-N [Fe].[Co].[Cu] Chemical class [Fe].[Co].[Cu] OBLMUVZPDITTKB-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- LIAWOTKNAVAKCX-UHFFFAOYSA-N hydrazine;dihydrochloride Chemical compound Cl.Cl.NN LIAWOTKNAVAKCX-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229910052920 inorganic sulfate Inorganic materials 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/033—Uronic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU76MA00002754A HU172831B (hu) | 1976-03-31 | 1976-03-31 | Sposob poluchenija kompleksov oligo- i poligalakturonnyk kislot s ionami zhiznenno vazhnykh metallov |
| HU2754/1976 | 1976-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52142018A JPS52142018A (en) | 1977-11-26 |
| JPS5942683B2 true JPS5942683B2 (ja) | 1984-10-17 |
Family
ID=10998832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52036878A Expired JPS5942683B2 (ja) | 1976-03-31 | 1977-03-31 | 必須金属イオン複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4225592A (enExample) |
| JP (1) | JPS5942683B2 (enExample) |
| AU (1) | AU513640B2 (enExample) |
| CH (1) | CH635111A5 (enExample) |
| DE (1) | DE2714128A1 (enExample) |
| DK (1) | DK139877A (enExample) |
| FI (1) | FI62102C (enExample) |
| FR (1) | FR2346367A1 (enExample) |
| GB (1) | GB1553749A (enExample) |
| HU (1) | HU172831B (enExample) |
| NL (1) | NL7703475A (enExample) |
| NO (1) | NO771122L (enExample) |
| SE (1) | SE7703709L (enExample) |
| SU (2) | SU886750A3 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54122731A (en) * | 1978-03-13 | 1979-09-22 | Takanao Nagae | Composition for treating hepatic disease |
| JPS5549996A (en) * | 1978-10-06 | 1980-04-11 | Fanuc Ltd | Motor drive system using pulse width modulation inverter |
| US4351735A (en) * | 1978-12-19 | 1982-09-28 | R.G.B. Laboratories Inc. | Mineral enrichment composition and method of preparing same |
| EP0024797A1 (en) * | 1979-07-13 | 1981-03-11 | Imperial Chemical Industries Plc | Chiral sugar complexes and process for their preparation |
| JPS57146713A (en) * | 1981-03-09 | 1982-09-10 | Akira Endo | Hypoglycemic |
| US4447336A (en) * | 1981-12-18 | 1984-05-08 | Monsanto Company | Stabilized galactomannan gum compositions |
| US4447337A (en) * | 1982-02-24 | 1984-05-08 | Monsanto Company | Stabiized galactomannan gum compositions |
| DE3228231A1 (de) * | 1982-07-28 | 1984-02-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung |
| DE3332301A1 (de) * | 1983-09-07 | 1985-03-21 | Algina AG, Zug | Metallsalze und metallmischsalze von polymeren, anionischen carbonsaeuren und/oder ihren schwefelsaeureestern, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und ihre verwendung |
| ES541277A0 (es) * | 1985-03-15 | 1985-12-16 | Vinas Lab | Procedimiento para la preparacion de un nuevo derivado de lafructosa |
| US4606831A (en) * | 1985-06-17 | 1986-08-19 | Monsanto Company | Stabilized galactomannan gum compositions |
| AU624065B2 (en) * | 1987-09-08 | 1992-06-04 | Kabushiki Kaisha Yakult Honsha | Liquid food |
| WO1990005750A1 (en) * | 1988-11-23 | 1990-05-31 | MTA Központi Kémiai Kutató Intézete | Basic metal complexes of acidic oligo- and polysaccharides and fruit and vegetable products and pharmaceutical compositions comprising such complexes |
| US5472950A (en) * | 1989-02-24 | 1995-12-05 | Richter Gedeon Vegyeszeti Gyar Rt. | Compositions containing cobalt hyaluronic acid complex |
| HU203372B (en) * | 1989-02-24 | 1991-07-29 | Richter Gedeon Vegyeszet | Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient |
| US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
| US5358702A (en) * | 1990-04-10 | 1994-10-25 | Unger Evan C | Methoxylated gel particle contrast media for improved diagnostic imaging |
| US5952308A (en) * | 1991-07-29 | 1999-09-14 | Pola Chemical Industries Inc. | Mineral absorption promoting agent |
| US5547945A (en) * | 1993-07-15 | 1996-08-20 | Jcr Pharmaceuticals Co., Ltd. | Remitting agent for nephrotic syndrome and hepatopathy symptoms |
| US5626881A (en) * | 1995-05-16 | 1997-05-06 | Menefee Mining Corporation | Humate dietary supplement |
| US7033615B2 (en) * | 1999-07-09 | 2006-04-25 | Cancer2 Inc. | Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| US20030228347A1 (en) * | 2000-09-12 | 2003-12-11 | Clark George H. | Amino acid chelate for the effective supplementation of calcium magnesium and potassium in the human diet |
| JP2004155766A (ja) * | 2002-10-18 | 2004-06-03 | Arita Junichi | 血糖降下作用を有する亜鉛含有物 |
| GB2430881B (en) * | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
| GB0707096D0 (en) * | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
| ES2625866T3 (es) | 2007-11-27 | 2017-07-20 | Algipharma As | Uso de oligómeros de alginatos para combatir las biopelículas |
| RU2404766C1 (ru) * | 2009-02-27 | 2010-11-27 | ГОУ ВПО Пятигорская Государственная фармацевтическая академия Министерства здравоохранения и социального развития РФ | Антиоксидантное лекарственное средство на основе зерновой послеспиртовой барды |
| GB0904941D0 (en) | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
| GB0904942D0 (en) | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
| SI2437783T1 (sl) | 2009-06-03 | 2014-04-30 | Algipharma As | Obdelava bakterije acinetobacter z alginatnimi oligomeri in antibiotiki |
| JP5721258B2 (ja) * | 2011-02-07 | 2015-05-20 | ヒガシマル醤油株式会社 | 鉄吸収促進剤 |
| US9566303B2 (en) | 2011-10-13 | 2017-02-14 | Vidasym, Inc. | Iron-fiber composition, preparation and uses thereof |
| UA116535C2 (uk) * | 2012-03-30 | 2018-04-10 | Рдінновейшн Апс | Сполуки бензолполікарбонових кислот та їх застосування як лікарських засобів |
| CA2901018C (en) | 2013-03-08 | 2022-05-03 | Vidasym, Inc. | Metal ion-functional fiber component complex compositions, preparation and uses thereof |
| PT3005872T (pt) * | 2013-06-05 | 2017-05-04 | Ahp Cropscience S L | Produto para regular a saúde de plantas, método para obter tal produto e utilização do mesmo |
| CN103435715A (zh) * | 2013-09-02 | 2013-12-11 | 中国科学院烟台海岸带研究所 | 寡糖及其衍生物钒配合物的制备方法及其应用 |
| RU2564949C1 (ru) * | 2014-10-06 | 2015-10-10 | Федеральное государственное бюджетное учреждение науки Институт органической и физической химии им. А.Е. Арбузова Казанского научного центра Российской академии наук | Фармакологическая композиция для повышения адаптационных возможностей организма в условиях физических нагрузок |
| RU2635762C1 (ru) * | 2017-02-27 | 2017-11-15 | Федеральное государственное бюджетное учреждение науки Институт органической и физической химии А.Е. Арбузова Казанского научного центра Российской академии наук | Гепатопротекторное средство |
| RU2704033C1 (ru) * | 2019-08-13 | 2019-10-23 | Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Казанский научный центр Российской академии наук" | Фармакологическая композиция на основе водорастворимых полиметаллокомплексов полигалактуроновой кислоты, стимулирующая процесс кроветворения |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2518135A (en) * | 1946-11-01 | 1950-08-08 | Univ Ohio State Res Found | Uniformly 2-substituted glucopyranose polymers |
| US3074927A (en) * | 1960-04-12 | 1963-01-22 | Paul D Saltman | Metallic complexes of reducing sugars |
| US3563978A (en) * | 1968-05-15 | 1971-02-16 | Irving L Ochs | Polyvalent metal complexes of natural polymers |
-
1976
- 1976-03-31 HU HU76MA00002754A patent/HU172831B/hu not_active IP Right Cessation
-
1977
- 1977-03-29 GB GB13137/77A patent/GB1553749A/en not_active Expired
- 1977-03-29 CH CH391877A patent/CH635111A5/de not_active IP Right Cessation
- 1977-03-29 FR FR7709354A patent/FR2346367A1/fr active Granted
- 1977-03-30 DE DE19772714128 patent/DE2714128A1/de not_active Withdrawn
- 1977-03-30 DK DK139877A patent/DK139877A/da not_active Application Discontinuation
- 1977-03-30 AU AU23764/77A patent/AU513640B2/en not_active Expired
- 1977-03-30 SE SE7703709A patent/SE7703709L/xx unknown
- 1977-03-30 FI FI770997A patent/FI62102C/fi not_active IP Right Cessation
- 1977-03-30 NO NO771122A patent/NO771122L/no unknown
- 1977-03-30 NL NL7703475A patent/NL7703475A/xx not_active Application Discontinuation
- 1977-03-31 SU SU772465854A patent/SU886750A3/ru active
- 1977-03-31 JP JP52036878A patent/JPS5942683B2/ja not_active Expired
-
1978
- 1978-01-13 SU SU782564404A patent/SU739077A1/ru active
-
1979
- 1979-02-12 US US06/011,421 patent/US4225592A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52142018A (en) | 1977-11-26 |
| US4225592A (en) | 1980-09-30 |
| SU739077A1 (ru) | 1980-06-05 |
| FI62102B (fi) | 1982-07-30 |
| HU172831B (hu) | 1978-12-28 |
| SE7703709L (sv) | 1977-10-01 |
| SU886750A3 (ru) | 1981-11-30 |
| GB1553749A (en) | 1979-09-26 |
| NO771122L (no) | 1977-10-03 |
| AU513640B2 (en) | 1980-12-11 |
| FI770997A7 (enExample) | 1977-10-01 |
| NL7703475A (nl) | 1977-10-04 |
| FI62102C (fi) | 1982-11-10 |
| AU2376477A (en) | 1978-10-05 |
| CH635111A5 (de) | 1983-03-15 |
| FR2346367A1 (fr) | 1977-10-28 |
| DE2714128A1 (de) | 1977-10-20 |
| DK139877A (da) | 1977-10-01 |
| FR2346367B1 (enExample) | 1980-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5942683B2 (ja) | 必須金属イオン複合体 | |
| US8058462B2 (en) | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation | |
| US2848366A (en) | Non-hydrated ferrous fumarate and hematinic composition thereof | |
| CN104402984B (zh) | 一种高载铁量的蛋白琥珀酸铁的制备方法 | |
| DK2125847T3 (en) | The ligand-modified poly oxo-hydroxy-metalionmaterialer, uses thereof and methods of preparation thereof | |
| JP2983171B2 (ja) | ピコリン酸−クロム複合物の新たな製造方法 | |
| US5107005A (en) | Process to obtain new mixed copper aminoactidate complexes from phenylate phenathrolines to be used as anticancerigenic agents | |
| EP1172110A2 (de) | Verwendung von Liponsäure zur Verbesserung der Bioverfügbarkeit von Mineralsalzen | |
| JP2017160447A (ja) | ベンゼンポリカルボン酸化合物及びその薬剤としての使用 | |
| WO2007117771A2 (en) | Time-release compositions for delivery of [cr3o(carboxylate)6(h2o)3]+ | |
| RU2141335C1 (ru) | Противоопухолевое средство "олипифат" и способ его получения | |
| DE69212947T2 (de) | Conalbumin und seine Derivate enthaltende Eisenkomplexe | |
| DE2759032C2 (enExample) | ||
| CN105601670B (zh) | 一种铬(iii)配合物及其制备方法和应用 | |
| CN100362021C (zh) | 山药多糖-铁复合物及其制备工艺 | |
| CN106928078A (zh) | 一种苏氨酸螯合铁及其应用 | |
| US3065138A (en) | Therapeutic preparations of elemental iron | |
| KR20050083679A (ko) | 인간 또는 동물 급식에 있어서 금속 킬레이트의 용도 | |
| CN108658849B (zh) | 一种Cr(III)配合物及其制备方法和应用 | |
| CN109311837A (zh) | 用于由氢氧化亚铁产生麦芽酚铁组合物的方法 | |
| JPH062047B2 (ja) | 人間生体内微量元素を高濃度に含有するスピルリナ類及びその生産方法 | |
| US1218472A (en) | Growth-controlling substance derived from the anterior lobe of the pituitary gland and process for producing the same. | |
| CN106588961A (zh) | 一种双核邻菲罗啉锌配合物及其合成方法与应用 | |
| Alimkhodzhaeva et al. | SYNTHESIS OF Cu (II), Co (II), Mn (II) COMPLEX COMBINES WITH ASPARAGIN ACID AND DETERMINATION OF THEIR MEDICAL-BIOLOGICAL PROPERTIES | |
| RU2355191C1 (ru) | Способ получения железосодержащей пищевой добавки |